GVAG
LGND icon

Great Valley Advisor Group’s Ligand Pharmaceuticals LGND Stock Holding History

Great Valley Advisor Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,341
Closed -$1.01M – 524
2020
Q4 		$1.01M Buy
+16,341
New +$932K 0.1% 181

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Great Valley Advisor Group's LGND Position: Q1 2021 in Review

Great Valley Advisor Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 16,341 shares — an estimated $1.01M sold.

Great Valley Advisor Group first reported a position in LGND in Q4 2020 and held it in 1 quarter. The position peaked at $1.01M in Q4 2020. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Great Valley Advisor Group reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Great Valley Advisor Group sold 16,341 Ligand Pharmaceuticals shares in Q1 2021, an estimated $1.01M.
  • Great Valley Advisor Group first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Great Valley Advisor Group's Ligand Pharmaceuticals position peaked at $1.01M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Great Valley Advisor Group's 13F filing for Q1 2021, filed 20 Apr 2021.